
Northern Ireland flags two deaths in GLP-1 weight‑loss drug safety reports
Two deaths in Northern Ireland were reported to the MHRA as potential adverse reactions to GLP‑1 weight‑loss medicines (one tied to Mounjaro, the other to an unspecified semaglutide product), among 511 suspected reports in NI over the last two years. The MHRA cautions that a reported reaction does not prove causation. The dataset also records six pancreatitis cases and shows heavy reporting from healthcare professionals. GLP‑1s are widely used for weight loss and diabetes; in NI, NHS access is restricted, with private options available for some patients. Safety reporting via the Yellow Card scheme is encouraged.



